Imagine what you can accomplish with 360° insight into the tumor immune response

Veracyte helps translate the complex tumor immune response into a clear path forward for our biopharma partners. We offer customized biomarker testing and analytical services to help them advance their therapeutic discovery, development and commercialization programs.

OUR CAPABILITIES FOR BIOPHARMA PARTNERS

Veracyte offers its biopharma partners unique, multi-omic capabilities, expertise and tools designed to optimize biomarkers, companion diagnostics and therapeutic clinical trials through robust analysis of patient oncology samples. Our Immuno-oncology (IO) capabilities focus largely on the immune contexture of tumors (type, density, location and immune functions), which is strongly related to tumor progression and clinical outcome in patients. We utilize multiple technologies and proprietary artificial intelligence platforms and databases to help our biopharma partners advance precision medicine in the era of immuno-oncology and combination therapies.

Veracyte’s IO capabilities leverage the pioneering work of Dr Jérôme Galon, recipient of the Prix Galien 2021 in the research category 

This prestigious award recognizes the greatest advancements in healthcare and is one of the industry's highest accolades.

Imagine what you can accomplish with 360° insight into the tumor immune response

FOR BIOPHARMA PARTNERS

Gain actionable insights to help accelerate the next generation of precision medicine in oncology with our multi-omic analysis of the tumor immune response, our unique Immunogram report and a comprehensive and proprietary cancer reference database made of genomic and immunomic biomarkers.

FOR IVD PARTNERS

Turn our experience into your success by partnering with Veracyte for any or all stages of your IVD development and manufacturing processes.

background-collage-mobile@2x

UPCOMING EVENTS

    Biotechgate Digital Partnering

    From 06 Feb To 10 Feb
    Virtual

    Xtalks webinar: A Tumor Microenvironment-Based Multiomics Analysis for Predictive Modelling

    From 09 Dec To 09 Dec
    Virtual

    SITC 37th Annual Meeting

    From 08 Nov To 12 Nov
    Boston

    MEDICEN DAY 2022

    From 29 Sep To 29 Sep
    Paris

Latest News

    VERACYTE COMPLETES ACQUISITION OF HALIODX

    3 August, 2021

    HALIODX AND VERACYTE SET PROPOSED ACQUISITION TERMS

    1 June, 2021

    IMMUNOSCORE® IS NOW AVAILABLE IN RECTAL CANCER FOR EXPERT CLINICAL CENTERS THROUGH AN INNOVATION ACCESS PROGRAM

    11 May, 2021

    HALIODX PARTNERS WITH DASA, THE LARGEST DIAGNOSTICS PROVIDER IN LATIN AMERICA, TO MAKE IMMUNOSCORE® AVAILABLE IN BRAZIL

    10 December, 2020

UPCOMING EVENTS

    Biotechgate Digital Partnering

    From 06 Feb To 10 Feb

    Virtual

    Xtalks webinar: A Tumor Microenvironment-Based Multiomics Analysis for Predictive Modelling

    From 09 Dec To 09 Dec

    Virtual

Featured Content